EGQ0 Stock Chart & Stats
€0.21
-€0.02(-5.23%)
At close: 4:00 PM EST
€0.21
-€0.02(-5.23%)
Day’s Range― - ―
52-Week Range€0.07 - €0.31
Previous CloseN/A
Volume0.00
Average Volume (3M)33.00
Market Cap
€11.83M
Enterprise Value€67.66M
Total Cash (Recent Filing)€9.35M
Total Debt (Recent Filing)€289.39K
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding140,775,450
10 Day Avg. Volume0
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio1.11
Price to Book (P/B)3.81
Price to Sales (P/S)166.47
P/FCF Ratio-10.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€1.19M
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low leverage limits financial risk and reduces the burden of interest or debt repayment while the company develops its diagnostics platform. This provides greater flexibility to allocate capital toward research, commercialisation, and partnerships over the next several quarters.
Platform BreadthThe company addresses both clinical diagnostics and research applications, creating multiple potential routes to commercial adoption rather than relying on one narrowly defined use case. A broader platform can support future product development, collaborations, and recurring customer relationships.
Reduced Losses Versus FY2022The improvement from the extreme FY2022 loss level indicates some progress in reducing the scale of earnings deterioration over time. If maintained alongside stronger commercial execution, this could provide a foundation for eventual operating leverage, even though current results remain unprofitable.
Bears Say
Sharp Revenue DeclineA revenue collapse of this magnitude weakens evidence of sustained customer demand and leaves the business operating below a scale that can support its cost base. Continued volatility would make commercial planning harder and delay the path toward self-funded growth.
Persistent Operating LossesLarge recurring losses show that current products and services are not yet generating enough gross profit to cover operating expenses. Until revenue expands materially or costs fall, the company is unlikely to demonstrate sustainable margins or dependable earnings power.
Ongoing Cash BurnPersistent negative operating cash flow means the business is funding operations and investment from its balance sheet rather than internally generated cash. The latest deterioration increases the importance of successful commercialisation and raises the risk of future funding needs.
Inoviq Ltd News
EGQ0 FAQ
What was Inoviq Ltd’s price range in the past 12 months?
Inoviq Ltd lowest stock price was €0.07 and its highest was €0.31 in the past 12 months.
What is Inoviq Ltd’s market cap?
Inoviq Ltd’s market cap is €11.83M.
When is Inoviq Ltd’s upcoming earnings report date?
Inoviq Ltd’s upcoming earnings report date is Feb 19, 2027 which is in 116 days.
How were Inoviq Ltd’s earnings last quarter?
Inoviq Ltd released its earnings results on Sep 16, 2026. The company reported -€0.015 earnings per share for the quarter.
Is Inoviq Ltd overvalued?
According to Wall Street analysts Inoviq Ltd’s price is currently Overvalued.
Does Inoviq Ltd pay dividends?
Inoviq Ltd does not currently pay dividends.
What is Inoviq Ltd’s EPS estimate?
Inoviq Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Inoviq Ltd have?
Inoviq Ltd has 140,775,450 shares outstanding.
What happened to Inoviq Ltd’s price movement after its last earnings report?
Inoviq Ltd reported an EPS of -€0.015 in its last earnings report. Following the earnings report the stock price went up 4.819%.
Which hedge fund is a major shareholder of Inoviq Ltd?
Currently, no hedge funds are holding shares in DE:EGQ0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inoviq Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:EGQ0 Sentiment 92%
Sector Average 67%
Sector Average 67%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.86%
12-Months-Change
Fundamentals
Return on Equity
-36.48%
Trailing 12-Months
Asset Growth
10.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inoviq Ltd
INOVIQ Ltd specializes in the research, development, and commercialization of diagnostic and exosome-based products, aiming to improve the detection and treatment of cancer and other conditions across Australia and the United States. Its current portfolio includes the hTERT test, an immunocytochemistry assay that serves as a supplementary tool for urine cytology in bladder cancer screening, alongside EXO-NET, designed for the capture and isolation of exosomes from liquid biopsy specimens. The company also boasts a robust diagnostic pipeline, featuring blood tests currently under development for various cancers, including ovarian and breast cancer. Originally incorporated in 1983 and formerly known as BARD1 Life Sciences Limited until its rebranding to INOVIQ Ltd in December 2021, the company maintains its headquarters in Notting Hill, Australia.
Technical Analysis
Genetic Technologies
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Imagion Biosystems Ltd.
―